

The microbiome in Asperger syndrome: A pilot study

Published: 21-11-2016

Last updated: 15-04-2024

The primary objective is determining whether there is a difference in faecal microbiome constitutions in individuals with Asperger syndrome compared to their non-affected sibs. The secondary objectives are whether there is a correlation between...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Psychiatric disorders NEC
Study type	Observational invasive

Summary

ID

NL-OMON49403

Source

ToetsingOnline

Brief title

MBA

Condition

- Psychiatric disorders NEC

Synonym

Asperger syndrome; autisme with normal cognition

Research involving

Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: aetiology, Asperger syndrome, autism, microbiome

Outcome measures

Primary outcome

Differences in results of the various gut microbiome constituents by HITChip flora mapping, between each Asperger individual and his/her sib, and between the group of Asperger individuals and the group of sibs

Secondary outcome

- a. Determining whether a difference in microbiome, if present, correlates with the diet
- b. Determining whether there is a correlation between bacterial DNA in platelets and bacterial fecal composition

Study description

Background summary

Autism is a well-known behavioural characteristic which has a high prevalence in individuals with intellectual disability. Autism that goes along with intellectual disability is known to have a very large number of causes, especially chromosome imbalances and changes in Mendelian genes. Asperger syndrome is characterized by autism but with near-typical language development and without intellectual disability. Studies to detect causes of Asperger syndrome have invariably failed to show abnormalities; especially no chromosome anomalies or mutations in Mendelian genes can be detected. This indicates there may be non-genetic causes. We suggest here that one of the causative factors may be a disturbance in the gut microbiome. There is growing evidence of a strong brain-gut axis, and an association between the gut microbiome and behaviour. Several small studies have indicated that individuals with autism plus intellectual disability can have a microbiome that differs from the microbiome in neurotypical individuals. To date, no microbiome studies have been done in individuals with Asperger syndrome however.

The way a gut-brain axis functions is at present unknown. We suggest the *transport* of microbiome information works through thrombocytes, and that there is a local action through a change in the methylation status of brain cells.

Study objective

The primary objective is determining whether there is a difference in faecal microbiome constitutions in individuals with Asperger syndrome compared to their non-affected sibs. The secondary objectives are whether there is a correlation between microbial DNA in thrombocytes and the microbiome. We will also investigate whether this is influenced by the diet.

Study design

Pilot case-control study

Study burden and risks

The burden of registering the normal diet of participants for 2 days represents a negligible burden and also the single harvesting of faeces, performed at home, is no burden. Only the blood sampling is a burden especially in the children aged 12-18years. We have considered performing the study in adults only. However we reasoned that irrespective the results in adults this study needs to be performed in children as well, as it remains uncertain whether results in adults can be translated to the paediatric group and vice versa. As a single blood sampling in the group 12-18years is still a limited burden, and as the study has the potential to offer a significant benefit to the group of children with Asperger as a whole, we considered it acceptable to perform the study in children.

Contacts

Public

Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105AZ
NL

Scientific

Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105AZ

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years)

Adolescents (16-17 years)

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Patients

- diagnosis Asperger syndrome as established by an experienced psychiatrist
- willing and able to donate a faeces sample, register diet and donate a single blood sample
- able to provide informed consent

Controls

- sib of individual with Asperger but without symptoms of Asperger syndrome as established by an experienced psychiatrist
- willing and able to donate a faeces sample, register diet and donate a single blood sample
- able to provide informed consent

Exclusion criteria

- use of probiotica
- recent antibiotics use (last 3 months)

Study design

Design

Study type:	Observational invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)

Primary purpose: Basic science

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	15-10-2018
Enrollment:	40
Type:	Actual

Ethics review

Approved WMO	
Date:	21-11-2016
Application type:	First submission
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL59303.018.16